I do not portend to be a business expert in biotechnology companies. That said, it is safe to say that adding value to a potential buyout can only occur when there is objective, concrete added value of the spinoff companies.
In our case, I lost money on ENTB when the "buyout" of a vet practice, one in many that was to occur in order to apply ENTB's potential development of animal stem cell treatments ended rather badly as I recall with a lawsuit and Koos having to turn the practice back over to original entity.
After that, nothing concrete was ever brought forward as I recall. In fact, I was surprised when C. Ichim was brought to ENTB late last year, but maybe this was some type of "trial period" where she could do animal testing and Koos could evaluate her work for what ended up being her hiring by RGBP.
We can only guess at the somewhat strange scenario of multiple companies and spinoffs, but to my knowledge, the only real value and action currently is in RGBP. Does ENTB or Zander even own any IP?
News 
Market Data 
Discover 
